Alisa Vital'EVna Vitebskaya

Alisa Vital'EVna Vitebskaya

Auto-generated profile, based on publicly available information

Alisa Vital'EVna Vitebskaya

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
OGOleg Glotov
Oleg Glotov
KSKirill Savostyanov
Kirill Savostyanov
TNTatyana S. Nagornova
Tatyana S. Nagornova
Alexander N ChernovAlexander N Chernov
Alexander N Chernov
MFMikhail A. Fedyakov
Mikhail A. Fedyakov
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
(1) Hypophosphatasia (HPP) is a rare inherited disease caused by mutations (pathogenic variants) in the ALPL gene which encodes tissue-nonspecific alkaline phosphatase (TNSALP). HPP is characterized by impaired bone mineral metabolism due to the low enzymatic activity of TNSALP. Knowledge about the structure of the gene and the features and functions of various ALPL gene variants, taking into account population specificity, gives an understanding of the hereditary nature of the disease, and contributes to the diagnosis, prevention, and treatment of the disease. The purpose of the study was to describe the spectrum and analyze the functional features of the ALPL gene variants, considering various HPP subtypes and clinical symptoms in Russian children. (2) From 2014–2021, the study included the blood samples obtained from 1612 patients with reduced alkaline phosphatase activity. The patients underwent an examination with an assessment of their clinical symptoms and biochemical levels of TNSALP. DNA was isolated from dried blood spots (DBSs) or blood from the patients to search for mutations in the exons of the ALPL gene using Sanger sequencing. The PCR products were sequenced using a reagent BigDye Terminator 3.1 kit (Applied Biosystems). Statistical analysis was performed using the GraphPad Prism 8.01 software. (3) The most common clinical symptoms in Russian patients with HPP and two of its variants (n = 22) were bone disorders (75%), hypomyotonia (50%), and respiratory failure (50%). The heterozygous carriage of the causal variants of the ALPL gene was detected in 225 patients. A total of 2 variants were found in 27 patients. In this group (n = 27), we identified 28 unique variants of the ALPL gene, of which 75.0% were missense, 17.9% were frameshift, 3.6% were splicing variants, and 3.6% were duplications. A total of 39.3% (11/28) of the variants were pathogenic, with two variants being probably pathogenic, and 15 variants had unknown clinical significance (VUS). Among the VUS group, 28.6% of the variants (7/28) were discovered by us for the first time. The most common variants were c.571G > A (p.Glu191Lys) and c.1171del (Arg391Valfs*12), with frequencies of 48.2% (13/28) and 11% (3/28), respectively. It was found that the frequency of nonsense variants of the ALPL gene was higher (p < 0.0001) in patients with the perinatal form compared to the infantile and childhood forms of HPP. Additionally, the number of homozygotes in patients with the perinatal form exceeded (p < 0.01) the frequencies of these genotypes in children with infantile and childhood forms of HPP. On the contrary, the frequencies of the compound-heterozygous and heterozygous genotypes were higher (p < 0.01) in patients with infantile childhood HPP than in perinatal HPP. In the perinatal form, residual TNSALP activity was lower (p < 0.0005) in comparison to the infantile and childhood (p < 0.05) forms of HPP. At the same time, patients with the heterozygous and compound-heterozygous genotypes (mainly missense variants) of the ALPL gene had greater residual activity (of the TNSALP protein) regarding those homozygous patients who were carriers of the nonsense variants (deletions and duplications) of the ALPL gene. Residual TNSALP activity was lower (p < 0.0001) in patients with pathogenic variants encoding the amino acids from the active site and the calcium and crown domains in comparison with the nonspecific region of the protein.

13 November 2015 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
AVAlisa V. Vitebskaya
Alisa V. Vitebskaya
EPElena A. Pisareva
Elena A. Pisareva
APAnastasia V. Popovich
Anastasia V. Popovich
Introduction. Growth of obesity prevalence in children and adolescents is a serious problem of modern medicine. To learn characteristics of patient’s behaviour, their dietary preference, feeding time and physical loads one can use specialized questionnaires.Aim. Evaluation of lifestyle, physical activity, dietary regimen and consumption of some meals according to results of questioning childrenand adolescents with obesity and their parents.Materials and methods. Hundreds of children and adolescents with obesity 10–17 years and their parents answered the questionnaire onage of obesity onset, its causes, physical activity and nutrition.Results and conclusion. Obesity develops more often at the age of 7–10 years. The most commonly insufficient physical activity and heredity. Specific characteristics of sedentary lifestyle and impared dietary regimen were identified. Comparison of patients’ and parents’ answers allowed to demonsrate the differense in attitude to the problem of obesity and to diminish the influence of not transparant answers on the results of investigation.

29 January 2024 in Genes
Verified
Journal Article
Open access
PDF file
Valeriia KovalskaiaValeriia Kovalskaia
Valeriia Kovalskaia
AKAnastasiia L. Kungurtseva
Anastasiia L. Kungurtseva
FBFatima Bostanova
Fatima Bostanova
PVPetr Vasilev
Petr Vasilev
VTVyacheslav Y. Tabakov
Vyacheslav Y. Tabakov
OROxana Ryzhkova
Oxana Ryzhkova
Bi-allelic pathogenic variations within POLR3A have been associated with a spectrum of hereditary disorders. Among these, a less frequently observed condition is Wiedemann–Rautenstrauch syndrome (WRS), also known as neonatal progeroid syndrome. This syndrome typically manifests neonatally and is characterized by growth retardation, evident generalized lipodystrophy with distinctively localized fat accumulations, sparse scalp hair, and atypical facial features. Our objective was to elucidate the underlying molecular mechanisms of Wiedemann–Rautenstrauch syndrome (WRS). In this study, we present a clinical case of a 7-year-old female patient diagnosed with WRS. Utilizing whole-exome sequencing (WES), we identified a novel missense variant c.3677T>C (p.Leu1226Pro) in the POLR3A gene (NM_007055.4) alongside two cis intronic variants c.1909+22G>A and c.3337-11T>C. Via the analysis of mRNA derived from fibroblasts, we reconfirmed the splicing-affecting nature of the c.3337-11T>C variant. Furthermore, our investigation led to the reclassification of the c.3677T>C (p.Leu1226Pro) variant as a likely pathogenic variant. Therefore, this is the first case demonstrating the molecular genetics of a patient with Wiedemann–Rautenstrauch syndrome from the Russian Federation. A limited number of clinical cases have been documented until this moment; therefore, broadening the linkage between phenotype and molecular changes in the POLR3A gene will significantly contribute to the comprehensive understanding of the molecular basis of POLR3A-related disorders.

20 August 2019 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
MAMikhail Antsiferov
Mikhail Antsiferov
GGGagik Galstyan
Gagik Galstyan
AZAlexey Zilov
Alexey Zilov
AMAlexander Mayorov
Alexander Mayorov
TMTatyana Markova
Tatyana Markova
AVAlisa Vitebskaya
Alisa Vitebskaya
The Scientific Advisory Board, chaired by Professor G. R. Galstyan (cochair - A.V. Zilov), met in Moscow on 19 June 2018 to discuss the possibilities of improving the results of diabetes mellitus (DM) treatment by considering glycaemic variability (GV) as an additional criterion for effective glycaemic control (especially in patients receiving insulin therapy) and as one of the goals of treatment in patients with unstable glycaemia. The purpose of the working meeting was to develop a strategy for the introduction of GV as a predictor and as an additional criterion for assessing the effectiveness and safety of hypoglycaemic therapy to improve the pharmacotherapy of diabetes and reduce cardiovascular and total mortality. The aims of the working meeting were to conduct a comprehensive data analysis of the relationship between GV and hypoglycaemia; to gather and analyse published data and the experience of decrease in GV and improved outcomes of diabetes against the background of different types of insulin therapy; to compare existing methods of glycaemia monitoring and GV assessment and examine their validity and availability in real practice in the context of limited budget and to analyse the informativeness and clinical and prognostic significance of various parameters of GV assessment and to determine their reasonable minimum for a comprehensive assessment of GV as a criterion for evaluating the effectiveness of DM treatment and the predictors of negative diabetes outcomes. The following reports were presented during the discussion: Glycemic variability: clinical and prognostic value. Types of glycemic variability (Candidate of Medical Sciences, assistant Professor Zilov A.V.); Methods of assessment of variability of glycemia in clinical trials and routine practice (PhD, Professor Markova T. N.); Current international and national recommendations on glycemic monitoring (PhD, Professor Galstyan G. R.) and Peculiarities of glycemic variability and its evaluation among children and adolescents (Candidate of Medical Sciences Vitebskaya A.V.).

12 July 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AVA. V. Vitebskaya
A. V. Vitebskaya
AKA. E. Krasnovidova
A. E. Krasnovidova
ARA. M. Rimskaya
A. M. Rimskaya
Introduction. Glucometers are the most available devices for glycemic control in children with type 1 diabetes mellitus (DM1). Changing social conditions and development of modern technologies can influence patients' preferences.Aim. To study the factors affecting the choice and usage of glucometers in children and adolescents with DM1 in real clinical practiceMaterials and methods. In 06.2020-05.2021, 107 patients 12.0 (8.8; 15.0) years with DM1 for 4.4 (2.0; 7.6) years filled in a questionnaire about the usage of glucometers.Results and discussion. While questioning patients used glucometers Contour (34 patients, 31.7%), OneTouch (33, 30.8%), Accu-Check (33, 30.8%), Satellit (3, 2.8%), AiChek (1, 0.9%), Easy Touch (1, 0.9%). Children start to use glucometer together with parents at 4.5 (4.0; 5.3) years, by themselves - at 6.0 (5.0; 7.0) years. Do not clean hands before finger puncture 55 (51.4%) patients, use wet wipes - 24 (22.4%), use antiseptics - 26 (24.3%), wash hands with soap - 2 (1.9%). Episodes of inflammation at the sites of punctures were reported by 21 patients (19.6%); patients using antiseptics faced with inflammation significantly rarer than others - OR = 2.7 (95% CI 0.6-12.6). Errors of glucometers were reported by 48 (44.9%) patients independently to method how they clean hands. Choosing glucometers patients pay attention to accuracy (76, 71.0%), blood drop volume (48, 44.9%), memory amount (22, 20.6%), size of device (22, 20.6%), mobile application (17, 15.9%), invisibility (10, 9.3%), design (7, 6.5%); and lightening, comfortable blood pin, battery indicator, possibility to add blood sample (1 per each, 0.9%).Conclusion. Children and adolescents with DM1 use glucometers Contour, OneTouch, and Accu-Check more often. Self-dependent usage of glucometers starts at preschool age. The majority of patients do not clean hands before puncture of a finger; antiseptics usage decreases the probability of inflammation. Choosing glucometers patients pay attention to technical characteristics and comfort.

30 May 2014 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
AVAlisa Vital'EVna Vitebskaya
Alisa Vital'EVna Vitebskaya
We analyzed international consensuses of experts and clinical recommendations on diagnosis and treatment of Prader-Willi syndrome (PWS): PWS consensus diagnostic criteria (1993); US PWS Association (PWSA-USA) consensus statements on evaluating of breathing abnormalities (2007), osteoporosis (2008), growth hormone treatment in PWS (2000 and 2009); Endocrine society clinical practice guideline on Prevention and treatment of pediatric obesity (2008); the Second Expert Meeting of the Comprehensive Care of Patients with PWS Consensus published as Recommendations for the diagnosis and management of PWS (2008). Historical analysis and comparison of recommendations are presented in this review article. Absence of Russian clinical practice guidelines on PWS patients management makes necessary the detailed study of listed documents.